ReadeRx Therapeutics
RNA-based Cancer Therapeutics
Health Tech & Life Sciences
Non Active, Jul 2026 ceased to operate
Company Overview
Snapshot
Founded in January 2023, ReadeRx Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing novel cancer treatments.
Business overview
ReadeRx Therapeutics is a Health Tech & Life Sciences company focused on developing RNA-based cancer therapeutics. The company's core technology involves small molecule inhibitors targeting the RNA binding protein IGF2BP1, which plays a pivotal role in stabilizing pro-oncogenic RNAs in various cancers. By inhibiting IGF2BP1, ReadeRx aims to offer a new strategy for cancer therapy, serving the pharmaceutical and life sciences sectors.
Log in to access full profile ›Company Intelligence Q&A
- What is ReadeRx Therapeutics' primary focus?
- ReadeRx Therapeutics is focused on developing RNA-based cancer therapeutics, specifically targeting the RNA binding protein IGF2BP1 with small molecule inhibitors.
- When was ReadeRx Therapeutics founded?
- ReadeRx Therapeutics was founded in January 2023.
- What is the current status of ReadeRx Therapeutics?
- ReadeRx Therapeutics is currently non-active, having ceased to operate in July 2026.
- In which sector does ReadeRx Therapeutics operate?
- ReadeRx Therapeutics operates within the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Drugs Discovery & Development.
- What is the product stage of ReadeRx Therapeutics?
- ReadeRx Therapeutics' product is currently in the R&D stage, focusing on developing small molecule inhibitors targeting the RNA binding protein IGF2BP1 for cancer therapy.